After 28 days of CAL-101 treatment, plasma from CLL patients showed lower levels of CCL3/4 (Hoellenriegel et al., 2011) and CXCL13 (Brown et al., 2011; Hoellenriegel et al., 2011) and B-CLL from these patients showed lower levels of Akt phosphorylation (Brown et al., 2011; Hoellenriegel et al., 2011). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.